VIRAL INFECTION PREVALENCE IN Β-THALASSEMIA MAJOR PATIENTS RECEIVING FREQUENT BLOOD TRANSFUSIONS
Main Article Content
Keywords
Hemoglobin Thalassemia major, Thalassemia intermediate, Hepatitis B Virus, Hepatitis C Virus, Hepatitis E Virus, Deoxyribonucleic Acid.
Abstract
Background: β-thalassemia is a hereditary blood related disorder characterized by partial or complete loss of production of hemoglobin’s β globin chain, which leads to severe anemia. HCV infection is common concern in β-thalassemia patients, particularly due to multiple transfusion, with increased risk of acquiring blood born infections. The prevalence of HCV varies across different region and populations depending on screening method, transfusion practice and geographical factor. HBV and HIV infection also occur in β-thalassemia patients, primarily through blood transfusion and other mode of transmission like vertical transmission.
Objectives : The purpose of study was to find out the prevalence of HCV, HIV and HBV in β-thalassemia major patients who were receiving regular blood transfusions.
Methodology: A descriptive study was conducted in Pakistan Institute of Medical Sciences, Islamabad. This study included 127 patients of β-thalassemia major who were refer to tertiary care hospital in PIMS (Pakistan Institute of Medical Sciences). Patients of all age who were confirmed for β-thalassemia major were included in current study. Blood samples were collected from 127 β-thalassemia patients, and after serum separation screening for HCV, HBV and HIV were performed by ICT kit method.
Results: Out of 127 β-thalassemia patients, 78 (61.4%) were male and 49 (38.6) were female. Most affected age group was 0-10 years containing 54.3% patient population with mean age 11.3±5.8 years. Most common blood group among β-thalassemia patients was B 46 (36.2%) following O 39 (30.7%), A 32 (25.2%) and AB 10 (7.9%). 61 (48%) were HCV positive, and 1 (0.8%) was HBV positive. Antibodies against HIV were not detected in any samples. Statistical difference of HCV and HBV was found significant among different age groups (p-value <0.05) and non-significant in gender and blood groups (p-value >0.05).
Conclusion: The prevalence of HCV infection in patients with β-thalassemia is substantially higher than that of HBV and HIV. Older age patients are more vulnerable to HCV infection as compared to younger ones. This situation should be managed and monitored through the administration of antiviral DAAs for the treatment of HCV in patients received more blood transfusion.
Objectives : The purpose of study was to find out the prevalence of HCV, HIV and HBV in β-thalassemia major patients who were receiving regular blood transfusions.
Methodology: A descriptive study was conducted in Pakistan Institute of Medical Sciences, Islamabad. This study included 127 patients of β-thalassemia major who were refer to tertiary care hospital in PIMS (Pakistan Institute of Medical Sciences). Patients of all age who were confirmed for β-thalassemia major were included in current study. Blood samples were collected from 127 β-thalassemia patients, and after serum separation screening for HCV, HBV and HIV were performed by ICT kit method.
Results: Out of 127 β-thalassemia patients, 78 (61.4%) were male and 49 (38.6) were female. Most affected age group was 0-10 years containing 54.3% patient population with mean age 11.3±5.8 years. Most common blood group among β-thalassemia patients was B 46 (36.2%) following O 39 (30.7%), A 32 (25.2%) and AB 10 (7.9%). 61 (48%) were HCV positive, and 1 (0.8%) was HBV positive. Antibodies against HIV were not detected in any samples. Statistical difference of HCV and HBV was found significant among different age groups (p-value <0.05) and non-significant in gender and blood groups (p-value >0.05).
Conclusion: The prevalence of HCV infection in patients with β-thalassemia is substantially higher than that of HBV and HIV. Older age patients are more vulnerable to HCV infection as compared to younger ones. This situation should be managed and monitored through the administration of antiviral DAAs for the treatment of HCV in patients received more blood transfusion.
References
1. Abdullah, S. W., et al. (2023). "Advances and Breakthroughs in IRES-Directed Translation and Replication of Picornaviruses." Mbio 14(2): e00358-00323.
2. Abed, B. A. (2010). "PREVALENCE OF HEPATITIS C VIRUS (HCV) AMONG THALASSEMIAPATIENTS IN IBN-ALBALADY HOSPITAL." Al-Nahrain Journal of Science 13(1): 121-126.
3. Afreen, H., et al. (2023). "Assessment of the Infectious Status of Transmissible Transfusion Infections (Hepatitis B and C) among β-Thalassemia Major Patients of Karachi; A Multicenter Study by SBTA (Sindh Blood Transfusion Authority)." Pakistan Journal of Medical & Health Sciences 17(01): 675-675.
4. Ahmed Kiani, R., et al. (2016). "Epidemiology of transfusion transmitted infection among patients with β-thalassaemia major in Pakistan." Journal of blood transfusion 2016.
5. Ahmed, S., et al. (2021). "Thalassemia patients from baluchistan in Pakistan are infected with multiple hepatitis B or C virus strains." The American journal of tropical medicine and hygiene 104(4): 1569.
6. Akhtar, S., et al. (2020). "The prevalence of hepatitis C virus infection in β-thalassemia patients in Pakistan: a systematic review and meta-analysis." BMC public Health 20(1): 1-9.
7. Al-Sharifi, L. M., et al. (2019). "Prevalence of hepatitis B and C in thalassemic patients and its relation with type of thalassemia, frequency of blood transfusion, and spleen status." Med J Babylon 16(3).
8. Ali, S. A., et al. (2009). "Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors." International journal of infectious diseases 13(1): 9-19.
9. Alter, M. J. (2011). HCV routes of transmission: what goes around comes around. Seminars in liver disease, © Thieme Medical Publishers.
10. Anwar, I., et al. (2018). "Effectiveness of Iron Chelation Therapy Using Serum Ferritin Levels in Thalassemia Major Patients." International Journal of Pathology: 20-24.
11. Apidechkul, T., et al. (2021). "Epidemiology of thalassemia among the hill tribe population in Thailand." Plos one 16(2): e0246736.
12. Aydinok, Y. (2012). "Thalassemia." Hematology 17(sup1): s28-s31.
13. Babker, A. M. (2022). "An Overview on Thalassemia and Challenges During COVID-19." International Journal of Health Sciences(I): 3207-3220.
14. Bhavsar, H., et al. (2011). "Prevalence of HIV, Hepatitis B and Hepatitis C infection in Thalassemia major patients in tertiary care hospital, Gujarat." Nat J Integr Res Med 2: 47-50.
15. Branson, B. M., et al. (2006). "Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings." Morbidity and Mortality Weekly Report: Recommendations and Reports 55(14): 1-CE-4.
16. Cao, A. and R. Galanello (2010). "Beta-thalassemia." Genetics in medicine 12(2): 61-76.
17. Chak, E., et al. (2011). "Hepatitis C virus infection in USA: an estimate of true prevalence." Liver International 31(8): 1090-1101.
18. Chen, G. F., et al. (2017). "Treatment of chronic hepatitis B infection-2017." Liver International 37: 59-66.
19. Cohen, M. S., et al. (2011). "Acute HIV-1 infection." New England Journal of Medicine 364(20): 1943-1954.
20. Cooley, T. and P. Lee (1925). "Series of cases of splenomegaly and peculiar changes in the bones." Trans. Am. Pediat. Soc 37: 29.
21. COVID, V. A. (2021). "Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older—United States, 2022." City.
22. Date, T., et al. (2004). "Genotype 2a hepatitis C virus subgenomic replicon can replicate in HepG2 and IMY-N9 cells." Journal of Biological Chemistry 279(21): 22371-22376.
23. Datta, S., et al. (2012). "Molecular biology of the hepatitis B virus for clinicians." Journal of clinical and experimental hepatology 2(4): 353-365.
24. Delius, H., et al. (1983). "Structure of the hepatitis B virus genome." Journal of virology 47(2): 337- 343.
25. Din, G., et al. (2014). "Prevalence of hepatitis C virus infection among thalassemia patients: a perspective from a multi-ethnic population of Pakistan." Asian Pacific journal of tropical medicine 7: S127-S133.
26. Dominguez, J., et al. (1999). "Evaluation of a rapid immunochromatographic assay for the detection of Legionella antigen in urine samples." European Journal of Clinical Microbiology and Infectious Diseases 18: 896-898.
27. Dupinay, T., et al. (2013). "Discovery of naturally occurring transmissible chronic hepatitis B virus infection among Macaca fascicularis from Mauritius Island." Hepatology 58(5): 1610-1620.
28. Din, G., et al. (2014). "Prevalence of hepatitis C virus infection among thalassemia patients: a perspective from a multi-ethnic population of Pakistan." Asian Pacific journal of tropical medicine 7: S127-S133.
29. Dominguez, J., et al. (1999). "Evaluation of a rapid immunochromatographic assay for the detection of Legionella antigen in urine samples." European Journal of Clinical Microbiology and Infectious Diseases 18: 896-898.
30. Dupinay, T., et al. (2013). "Discovery of naturally occurring transmissible chronic hepatitis B virus infection among Macaca fascicularis from Mauritius Island." Hepatology 58(5): 1610-1620.
31. Farrell, G. C. (2007). New hepatitis C guidelines for the Asia–Pacific region: APASL consensus statements on the diagnosis, management and treatment of hepatitis C virus infection, Wiley Online Library. 22: 607-610.
32. Din, G., et al. (2014). "Prevalence of hepatitis C virus infection among thalassemia patients: a perspective from a multi-ethnic population of Pakistan." Asian Pacific journal of tropical medicine 7: S127-S133.
33. Dominguez, J., et al. (1999). "Evaluation of a rapid immunochromatographic assay for the detection of Legionella antigen in urine samples." European Journal of Clinical Microbiology and Infectious Diseases 18: 896-898.
34. Din, G., et al. (2014). "Prevalence of hepatitis C virus infection among thalassemia patients: a perspective from a multi-ethnic population of Pakistan." Asian Pacific journal of tropical medicine 7: S127-S133.
35. Dominguez, J., et al. (1999). "Evaluation of a rapid immunochromatographic assay for the detection of Legionella antigen in urine samples." European Journal of Clinical Microbiology and Infectious Diseases 18: 896-898.
36. Dupinay, T., et al. (2013). "Discovery of naturally occurring transmissible chronic hepatitis B virus infection among Macaca fascicularis from Mauritius Island." Hepatology 58(5): 1610-1620.
37. Farrell, G. C. (2007). New hepatitis C guidelines for the Asia–Pacific region: APASL consensus statements on the diagnosis, management and treatment of hepatitis C virus infection, Wiley Online Library. 22: 607-610.
38. Forget, B. G. and H. F. Bunn (2013). "Classification of the disorders of hemoglobin." Cold Spring Harbor perspectives in medicine 3(2): a011684.
39. Galanello, R. and R. Origa (2010). "Beta-thalassemia." Orphanet journal of rare diseases 5: 1-15.
40. Gilbert, M., et al. (2001). "Pathogenesis and immune." Neurology 56(758ą765): 13.
41. Din, G., et al. (2014). "Prevalence of hepatitis C virus infection among thalassemia patients: a perspective from a multi-ethnic population of Pakistan." Asian Pacific journal of tropical medicine 7: S127-S133.
42. Dominguez, J., et al. (1999). "Evaluation of a rapid immunochromatographic assay for the detection of Legionella antigen in urine samples." European Journal of Clinical Microbiology and Infectious Diseases 18: 896-898.
43. Din, G., et al. (2014). "Prevalence of hepatitis C virus infection among thalassemia patients: a perspective from a multi-ethnic population of Pakistan." Asian Pacific journal of tropical medicine 7: S127-S133.
44. Dominguez, J., et al. (1999). "Evaluation of a rapid immunochromatographic assay for the detection of Legionella antigen in urine samples." European Journal of Clinical Microbiology and Infectious Diseases 18: 896-898.
45. Dupinay, T., et al. (2013). "Discovery of naturally occurring transmissible chronic hepatitis B virus infection among Macaca fascicularis from Mauritius Island." Hepatology 58(5): 1610-1620.
46. Farrell, G. C. (2007). New hepatitis C guidelines for the Asia–Pacific region: APASL consensus statements on the diagnosis, management and treatment of hepatitis C virus infection, Wiley Online Library. 22: 607-610.
47. Forget, B. G. and H. F. Bunn (2013). "Classification of the disorders of hemoglobin." Cold Spring Harbor perspectives in medicine 3(2): a011684.
48. Galanello, R. and R. Origa (2010). "Beta-thalassemia." Orphanet journal of rare diseases 5: 1-15.
49. Gilbert, M., et al. (2001). "Pathogenesis and immune." Neurology 56(758ą765): 13.
50. Grebely, J., et al. (2017). "Elimination of HCV as a public health concern among people who inject drugs by 2030–What will it take to get there?" Journal of the International AIDS Society 20(1): 22146.
51. Gupta, B., et al. (2018). "Yoga research a scientometric assessment of global publications output during 2007-16." Pharmacognosy Journal 10(3).
52. Hadden, J. A., et al. (2018). "All-atom molecular dynamics of the HBV capsid reveals insights into biological function and cryo-EM resolution limits." Elife 7: e32478.
53. Hanif, M., et al. (2013). "Study of genotypes and subgenotypes of Hepatitis B virus prevalent in big cities of Pakistan." Afr J Microbiol Res 7(3): 152-157.
54. Hayder, I., et al. (2012). "Comparison of Different ICT Kits for HBsAg and Anti HCV Using Gold Standard ELISA." Pakistan Journal of Medical Research 51(3).
55. Hudna, A. S., et al. (2022). "Hepatitis B and C among Multi-Transfused Pediatric Thalassemic Patients in Sana'a City, Yemen: A Single-Center Retrospective Study." Yemeni Journal for Medical Sciences 16(1): 7-13.
56. Ishida, J. H., et al. (2008). "Influence of cannabis use on severity of hepatitis C disease." Clinical gastroenterology and hepatology 6(1): 69-75.
57. Jafroodi, M., et al. (2015). "Trend in prevalence of hepatitis C virus infection among β-thalassemia major patients: 10 years of experience in Iran." International journal of preventive medicine 6.
58. Jallab, H. R. and Z. M. Eesa (2020). "Prevalence of Hepatitis B and Hepatitis C Viruses in?– thalassemias major patient in AD-Diwanya privince, iraq." Indian Journal of Forensic Medicine & Toxicology 14(2): 743-747.
59. Janjua, N. and M. Nizamy (2004). "Knowledge and practices of barbers about hepatitis B and C transmission in Rawalpindi and Islamabad." Journal of Pakistan medical association 54(3): 116.
60. Kalim, M., et al. (2017). "Detection of HBV and HCV by ICT and ELISA Method in Different Areas of District Malakand." PSM Microbiology 2(1): 5-8.
61. Kandi, V., et al. (2021). "Hepatitis C viral infection among beta-thalassemia patients: a study from the centre for excellence in thalassemia and other blood disorders." Cureus 13(7).
62. Kato, N. (2000). "Genome of human hepatitis C virus (HCV): gene organization, sequence diversity, and variation." Microbial & comparative genomics 5(3): 129-151.
63. Khalil, S., et al. (2016). "Status of hepatitis B and C in beta thalassemia major patients." Journal of Islamabad Medical & Dental College (JIMDC) 5(2): 71-73.
64. Kidson-Gerber, G. L., et al. (2008). "Management and clinical outcomes of transfusion-dependent thalassaemia major in an Australian tertiary referral clinic." Medical journal of Australia 188(2): 72-75.
65. Kusumoto, S., et al. (2020). "Ultra-high sensitivity HBsAg assay can diagnose HBV reactivation following rituximab-based therapy in patients with lymphoma." Journal of hepatology 73(2): 285- 293.
66. Lai, M. W., et al. (2012). "Increased seroprevalence of HBV DNA with mutations in the s gene among individuals greater than 18 years old after complete vaccination." Gastroenterology 143(2): 400-407.
67. Lee, S. R., et al. (2011). "Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid." Journal of virological methods 172(1-2): 27-31.
68. Li, Y.-P., et al. (2014). "Differential Sensitivity of 5′ UTR-NS5A recombinants of hepatitis C virus genotypes 1− 6 to protease and NS5A inhibitors." Gastroenterology 146(3): 812-821. e814.
69. Liang, T. J. (2009). "Hepatitis B: the virus and disease." Hepatology 49(S5): S13-S21.
70. Lindenbach, B. D. and C. M. Rice (2003). "Molecular biology of flaviviruses." Advances in virus research 59: 23-62.
71. Luby, S., et al. (1997). "The relationship between therapeutic injections and high prevalence of hepatitis C infection in Hafizabad, Pakistan." Epidemiology & Infection 119(3): 349-356.
72. MacLachlan, J. H., et al. (2015). "Estimating the global prevalence of hepatitis B." The Lancet 386(10003): 1515-1517.
73. Mahmood, M., et al. (2022). "Identification of HBV and HCV transmission in multi-transfused Thalassemia patients of Azad Jammu and Kashmir, Pakistan." medRxiv: 2022.2001. 2025.22269811.
74. Lai, M. W., et al. (2012). "Increased seroprevalence of HBV DNA with mutations in the s gene among individuals greater than 18 years old after complete vaccination." Gastroenterology 143(2): 400-407.
75. Lee, S. R., et al. (2011). "Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid." Journal of virological methods 172(1-2): 27-31.
76. Lai, M. W., et al. (2012). "Increased seroprevalence of HBV DNA with mutations in the s gene among individuals greater than 18 years old after complete vaccination." Gastroenterology 143(2): 400-407.
77. Lai, M. W., et al. (2012). "Increased seroprevalence of HBV DNA with mutations in the s gene among individuals greater than 18 years old after complete vaccination." Gastroenterology 143(2): 400-407.
78. Lee, S. R., et al. (2011). "Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid." Journal of virological methods 172(1-2): 27-31.
79. Li, Y.-P., et al. (2014). "Differential Sensitivity of 5′ UTR-NS5A recombinants of hepatitis C virus genotypes 1− 6 to protease and NS5A inhibitors." Gastroenterology 146(3): 812-821. e814.
80. Liang, T. J. (2009). "Hepatitis B: the virus and disease." Hepatology 49(S5): S13-S21.
81. Lindenbach, B. D. and C. M. Rice (2003). "Molecular biology of flaviviruses." Advances in virus research 59: 23-62.
82. Luby, S., et al. (1997). "The relationship between therapeutic injections and high prevalence of hepatitis C infection in Hafizabad, Pakistan." Epidemiology & Infection 119(3): 349-356.
83. MacLachlan, J. H., et al. (2015). "Estimating the global prevalence of hepatitis B." The Lancet 386(10003): 1515-1517.
84. Mahmood, M., et al. (2022). "Identification of HBV and HCV transmission in multi-transfused Thalassemia patients of Azad Jammu and Kashmir, Pakistan." medRxiv: 2022.2001. 2025.22269811.
85. Mahmood, M. A., et al. (2004). "Prevalence of hepatitis B, C and HIV infection in blood donors of Multan region." Annals of King Edward Medical University 10(4).
86. Mansour-Ghanaei, F., et al. (2021). "Epidemiologic profile of viral hepatitis B and C in North of Iran: results from PERSIAN Guilan Cohort Study (PGCS)." BMC Research Notes 14: 1-7.
87. Marengo-Rowe, A. J. (2007). The thalassemias and related disorders. Baylor university medical center proceedings, Taylor & Francis.
88. Mettananda, D. S. G. (2015). Ameliorating β-thalassaemia by manipulating expression of the α- globin gene, University of Oxford.
89. Mirzaei, G., et al. (2021). "Prevalence of HBV and HCV infection in beta-thalassemia major patients of Tabriz city, Iran." New Microbes and New Infections 43: 100912.
90. Mohammadi, S. and M. Khodabandehloo (2017). "Prevalence of hepatitis C virus antibodies among beta-thalassemia major patients in Kurdistan Province, Iran." ARCHIVES OF CLINICAL INFECTIOUS DISEASES 12(3).
91. Mukherjee, K., et al. (2017). "Prevalence of hepatitis B and hepatitis C virus infection in repeatedly transfused thalassemics in a tertiary care hospital in eastern India." Int J Res Med Sci 5(10): 4558- 4562.
92. Mumtaz, K., et al. (2005). "Epidemiology and clinical pattern of hepatitis delta virus infection in Pakistan." Journal of gastroenterology and hepatology 20(10): 1503-1507.
93. Musa, B., et al. (2015). "Prevalence of hepatitis B virus infection in Nigeria, 2000-2013: a systematic review and meta-analysis." Nigerian journal of clinical practice 18(2): 163-172.
94. NADIR, R., et al. "Frequency of Hepatitis B and C in Beta Thalassemia Major with Multiple Blood Transfusions."
95. Nagral, A., et al. (2017). "Generic direct acting antivirals in treatment of chronic hepatitis C infection in patients of thalassemia major." Journal of clinical and experimental hepatology 7(3): 172-178.
96. Nguyen, D. H., et al. (2008). "Hepatitis B virus–cell interactions and pathogenesis." Journal of cellular physiology 216(2): 289-294.
97. Nienhuis, A. W. and D. G. Nathan (2012). "Pathophysiology and clinical manifestations of the β- thalassemias." Cold Spring Harbor perspectives in medicine 2(12): a011726.
98. Noguchi, C., et al. (2004). "Reducing oxidative damage and cell dehydration in thalassemia." Haematologica 89: 1281-1283.
99. Mohammadi, S. and M. Khodabandehloo (2017). "Prevalence of hepatitis C virus antibodies among beta-thalassemia major patients in Kurdistan Province, Iran." ARCHIVES OF CLINICAL INFECTIOUS DISEASES 12(3).
100. Mukherjee, K., et al. (2017). "Prevalence of hepatitis B and hepatitis C virus infection in repeatedly transfused thalassemics in a tertiary care hospital in eastern India." Int J Res Med Sci 5(10): 4558- 4562.
101. Mumtaz, K., et al. (2005). "Epidemiology and clinical pattern of hepatitis delta virus infection in Pakistan." Journal of gastroenterology and hepatology 20(10): 1503-1507.
102. Musa, B., et al. (2015). "Prevalence of hepatitis B virus infection in Nigeria, 2000-2013: a systematic review and meta-analysis." Nigerian journal of clinical practice 18(2): 163-172.
103. NADIR, R., et al. "Frequency of Hepatitis B and C in Beta Thalassemia Major with Multiple Blood Transfusions."
104. Nagral, A., et al. (2017). "Generic direct acting antivirals in treatment of chronic hepatitis C infection in patients of thalassemia major." Journal of clinical and experimental hepatology 7(3): 172-178.
105. Nguyen, D. H., et al. (2008). "Hepatitis B virus–cell interactions and pathogenesis." Journal of cellular physiology 216(2): 289-294.
106. Nienhuis, A. W. and D. G. Nathan (2012). "Pathophysiology and clinical manifestations of the β- thalassemias." Cold Spring Harbor perspectives in medicine 2(12): a011726.
107. Noguchi, C., et al. (2004). "Reducing oxidative damage and cell dehydration in thalassemia." Haematologica 89: 1281-1283.
108. Origa, R. (2023). "Hepatitis C and Thalassemia: A Story with (Almost) a Happy Ending." Pathogens 12(5): 683.
109. Page, K., et al. (2013). "Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention." Clinical infectious diseases 57(suppl_2): S32-S38.
110. Parkash, A., et al. (2022). "Effectiveness And Safety Of Direct Acting Antiviral Agents In Thalassaemic Patients With Chronic Hepatitis C." Journal of Ayub Medical College, Abbottabad: JAMC 34(3): 447-451.
111. Patel, P., et al. (2012). "Rapid HIV screening: missed opportunities for HIV diagnosis and prevention." Journal of Clinical Virology 54(1): 42-47.
112. Peeling, R. W., et al. (2006). "Rapid tests for sexually transmitted infections (STIs): the way forward." Sexually transmitted infections 82(suppl 5): v1-v6.
113. Pol, S., et al. (2012). "Hepatitis C: epidemiology, diagnosis, natural history and therapy." Hepatitis C in renal disease, hemodialysis and transplantation 176: 1-9.
114. Puno, S. N., et al. (2021). Prevalence of Hepatitis B and Hepatitis C Among Patients of Thalassemia Major at a Teaching Hospital in Larkana. Med. Forum.
115. Qurat-ul-Ain, L. A., et al. (2011). "Prevalence of β-thalassemic patients associated with consanguinity and anti-HCV-antibody positivity–a cross sectional study." Pak J Zool 43(1): 29-36.
116. Riaz, M., et al. (2022). "Prevalence of transfusion-transmitted infections in multiple blood transfusion-dependent thalassemic patients in Asia: A systemic review." International Journal of Immunopathology and Pharmacology 36: 03946320221096909.
117. Schweitzer, A., et al. (2015). "Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013." The Lancet 386(10003): 1546-1555.
118. Seeger, C. and W. S. Mason (2000). "Hepatitis B virus biology." Microbiology and molecular biology reviews 64(1): 51-68.
119. Shahzadi, N., et al. (2023). "Efficacy of Sofosbuvir and Ribavirin in Children Presenting with Hepatitis C at Tertiary Care Hospital, Faisalabad." Journal of Bahria University Medical and Dental College 13(02): 82-86.
120. Silva, A. P. d. (2015). Desenvolvimento de métodos de diagnóstico, silenciamento gênico e caracterização molecular do vírus herpes simples tipo 1 e herpesvírus humano tipo 6 em pacientes imunocomprometidos do Rio de Janeiro.
121. Sinha, M. K., et al. (2019). "Menace of Hepatitis C virus among multitransfused thalassemia patients in Balasore district of Odisha state in India." Journal of Family Medicine and Primary Care 8(9): 2850.
122. Sluis-Cremer, N. and G. Tachedjian (2008). "Mechanisms of inhibition of HIV replication by non- nucleoside reverse transcriptase inhibitors." Virus research 134(1-2): 147-156.
123. Smith-Palmer, J., et al. (2015). "Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits." BMC infectious diseases 15(1): 1-19.
124. Stanaway, J. D., et al. (2016). "The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013." The Lancet 388(10049): 1081-1088.
125. Strader, D. B., et al. (2004). "Diagnosis, management, and treatment of hepatitis C." Hepatology 39(4): 1147-1171.
126. Strehlow, A. J., et al. (2012). "Hepatitis C among clients of health care for the homeless primary care clinics." Journal of health care for the poor and underserved 23(2): 811-833.
127. Syed, F. N., et al. (2023). "Hepatitis C Virus Infection in Patients with Beta Thalassemia after Multiple Transfusions at a Tertiary Care Hospital." Pakistan Journal of Medical & Health Sciences 17(01): 363-363.
128. Tang, W., et al. (2017). "Diagnostic accuracy of tests to detect Hepatitis C antibody: a meta-analysis and review of the literature." BMC infectious diseases 17: 39-57.
129. Terrault, N. A., et al. (2018). "Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance." Hepatology 67(4): 1560-1599.
130. Thein, S. L. (2018). "Molecular basis of β thalassemia and potential therapeutic targets." Blood Cells, Molecules, and Diseases 70: 54-65.
131. Tiollais, P., et al. (1985). "The hepatitis B virus." Nature 317(6037): 489-495.
132. Tong, S. and P. Revill (2016). "Overview of hepatitis B viral replication and genetic variability." Journal of hepatology 64(1): S4-S16.
133. Torti, L., et al. (2020). "Impact of SARS CoV-2 in hemoglobinopathies with immune disfunction and epidemiology. A protective mechanism from beta chain hemoglobin defects?" Mediterranean journal of hematology and infectious diseases 12(1).
134. Valentine, W. N. and J. V. Neel (1944). "Hematologic and Genetic Study of the Transmission Of Thalassemia:(Cooley's Anemia; Mediterranean Anemia)." Archives of internal medicine 74(3): 185-196.
135. Vichinsky, E. P. (2005). "Changing patterns of thalassemia worldwide." Annals of the New York Academy of Sciences 1054(1): 18-24.
136. Vichinsky, E. P. (2009). "Alpha thalassemia major—new mutations, intrauterine management, and outcomes." ASH Education Program Book 2009(1): 35-41.
137. Vichinsky, E. P. (2013). "Clinical manifestations of α-thalassemia." Cold Spring Harbor perspectives in medicine 3(5): a011742.
138. Wahed, A., et al. (2019). "Hematology and coagulation: a comprehensive review for board preparation, certification and clinical practice."
139. Waheed, U., et al. (2019). "Evaluation of screening effectiveness of hepatitis B surface antigen and anti-HCV rapid test kits in Pakistan." Journal of Laboratory Physicians 11(04): 369-372.
140. Waheed, Y., et al. (2009). "Hepatitis C virus in Pakistan: a systematic review of prevalence, genotypes and risk factors." World journal of gastroenterology: WJG 15(45): 5647.
141. Weatherall, D. (2000). "Introduction to the Problem of Hemoglobin E-β Thalassemia." Journal of Pediatric Hematology/Oncology 22(6): 551.
142. Weatherall, D. and J. Clegg (2001). Historical perspectives: in The Thalassemia syndromes 4th edition, Blackwell Scientific, Oxford UK.
143. Torti, L., et al. (2020). "Impact of SARS CoV-2 in hemoglobinopathies with immune disfunction and epidemiology. A protective mechanism from beta chain hemoglobin defects?" Mediterranean journal of hematology and infectious diseases 12(1).
144. Valentine, W. N. and J. V. Neel (1944). "Hematologic and Genetic Study of the Transmission Of Thalassemia:(Cooley's Anemia; Mediterranean Anemia)." Archives of internal medicine 74(3): 185-196.
145. Vichinsky, E. P. (2005). "Changing patterns of thalassemia worldwide." Annals of the New York Academy of Sciences 1054(1): 18-24.
146. Vichinsky, E. P. (2009). "Alpha thalassemia major—new mutations, intrauterine management, and outcomes." ASH Education Program Book 2009(1): 35-41.
147. Vichinsky, E. P. (2013). "Clinical manifestations of α-thalassemia." Cold Spring Harbor perspectives in medicine 3(5): a011742.
148. Wahed, A., et al. (2019). "Hematology and coagulation: a comprehensive review for board preparation, certification and clinical practice."
149. Waheed, U., et al. (2019). "Evaluation of screening effectiveness of hepatitis B surface antigen and anti-HCV rapid test kits in Pakistan." Journal of Laboratory Physicians 11(04): 369-372.
150. Waheed, Y., et al. (2009). "Hepatitis C virus in Pakistan: a systematic review of prevalence, genotypes and risk factors." World journal of gastroenterology: WJG 15(45): 5647.
151. Weatherall, D. (2000). "Introduction to the Problem of Hemoglobin E-β Thalassemia." Journal of Pediatric Hematology/Oncology 22(6): 551.
152. Weatherall, D. and J. Clegg (2001). Historical perspectives: in The Thalassemia syndromes 4th edition, Blackwell Scientific, Oxford UK.
153. Whipple, G. H. and W. L. Bradford (1936). "Mediterranean disease-thalassemia (erythroblastic anemia of Cooley): associated pigment abnormalities simulating hemochromatosis." The Journal of Pediatrics 9(3): 279-311.
154. Yu, S., et al. (2020). "Burden of Acute Viral Hepatitis—China, 1990− 2019." China CDC Weekly 2(31): 579.
155. Zamani, F., et al. (2018). "The effectiveness of sofosbuvir and daclatasvir in the treatment of hepatitis C in thalassaemia major patients and their effect on haematological factors." Indian journal of medical microbiology 36(2): 224-22
2. Abed, B. A. (2010). "PREVALENCE OF HEPATITIS C VIRUS (HCV) AMONG THALASSEMIAPATIENTS IN IBN-ALBALADY HOSPITAL." Al-Nahrain Journal of Science 13(1): 121-126.
3. Afreen, H., et al. (2023). "Assessment of the Infectious Status of Transmissible Transfusion Infections (Hepatitis B and C) among β-Thalassemia Major Patients of Karachi; A Multicenter Study by SBTA (Sindh Blood Transfusion Authority)." Pakistan Journal of Medical & Health Sciences 17(01): 675-675.
4. Ahmed Kiani, R., et al. (2016). "Epidemiology of transfusion transmitted infection among patients with β-thalassaemia major in Pakistan." Journal of blood transfusion 2016.
5. Ahmed, S., et al. (2021). "Thalassemia patients from baluchistan in Pakistan are infected with multiple hepatitis B or C virus strains." The American journal of tropical medicine and hygiene 104(4): 1569.
6. Akhtar, S., et al. (2020). "The prevalence of hepatitis C virus infection in β-thalassemia patients in Pakistan: a systematic review and meta-analysis." BMC public Health 20(1): 1-9.
7. Al-Sharifi, L. M., et al. (2019). "Prevalence of hepatitis B and C in thalassemic patients and its relation with type of thalassemia, frequency of blood transfusion, and spleen status." Med J Babylon 16(3).
8. Ali, S. A., et al. (2009). "Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors." International journal of infectious diseases 13(1): 9-19.
9. Alter, M. J. (2011). HCV routes of transmission: what goes around comes around. Seminars in liver disease, © Thieme Medical Publishers.
10. Anwar, I., et al. (2018). "Effectiveness of Iron Chelation Therapy Using Serum Ferritin Levels in Thalassemia Major Patients." International Journal of Pathology: 20-24.
11. Apidechkul, T., et al. (2021). "Epidemiology of thalassemia among the hill tribe population in Thailand." Plos one 16(2): e0246736.
12. Aydinok, Y. (2012). "Thalassemia." Hematology 17(sup1): s28-s31.
13. Babker, A. M. (2022). "An Overview on Thalassemia and Challenges During COVID-19." International Journal of Health Sciences(I): 3207-3220.
14. Bhavsar, H., et al. (2011). "Prevalence of HIV, Hepatitis B and Hepatitis C infection in Thalassemia major patients in tertiary care hospital, Gujarat." Nat J Integr Res Med 2: 47-50.
15. Branson, B. M., et al. (2006). "Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings." Morbidity and Mortality Weekly Report: Recommendations and Reports 55(14): 1-CE-4.
16. Cao, A. and R. Galanello (2010). "Beta-thalassemia." Genetics in medicine 12(2): 61-76.
17. Chak, E., et al. (2011). "Hepatitis C virus infection in USA: an estimate of true prevalence." Liver International 31(8): 1090-1101.
18. Chen, G. F., et al. (2017). "Treatment of chronic hepatitis B infection-2017." Liver International 37: 59-66.
19. Cohen, M. S., et al. (2011). "Acute HIV-1 infection." New England Journal of Medicine 364(20): 1943-1954.
20. Cooley, T. and P. Lee (1925). "Series of cases of splenomegaly and peculiar changes in the bones." Trans. Am. Pediat. Soc 37: 29.
21. COVID, V. A. (2021). "Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older—United States, 2022." City.
22. Date, T., et al. (2004). "Genotype 2a hepatitis C virus subgenomic replicon can replicate in HepG2 and IMY-N9 cells." Journal of Biological Chemistry 279(21): 22371-22376.
23. Datta, S., et al. (2012). "Molecular biology of the hepatitis B virus for clinicians." Journal of clinical and experimental hepatology 2(4): 353-365.
24. Delius, H., et al. (1983). "Structure of the hepatitis B virus genome." Journal of virology 47(2): 337- 343.
25. Din, G., et al. (2014). "Prevalence of hepatitis C virus infection among thalassemia patients: a perspective from a multi-ethnic population of Pakistan." Asian Pacific journal of tropical medicine 7: S127-S133.
26. Dominguez, J., et al. (1999). "Evaluation of a rapid immunochromatographic assay for the detection of Legionella antigen in urine samples." European Journal of Clinical Microbiology and Infectious Diseases 18: 896-898.
27. Dupinay, T., et al. (2013). "Discovery of naturally occurring transmissible chronic hepatitis B virus infection among Macaca fascicularis from Mauritius Island." Hepatology 58(5): 1610-1620.
28. Din, G., et al. (2014). "Prevalence of hepatitis C virus infection among thalassemia patients: a perspective from a multi-ethnic population of Pakistan." Asian Pacific journal of tropical medicine 7: S127-S133.
29. Dominguez, J., et al. (1999). "Evaluation of a rapid immunochromatographic assay for the detection of Legionella antigen in urine samples." European Journal of Clinical Microbiology and Infectious Diseases 18: 896-898.
30. Dupinay, T., et al. (2013). "Discovery of naturally occurring transmissible chronic hepatitis B virus infection among Macaca fascicularis from Mauritius Island." Hepatology 58(5): 1610-1620.
31. Farrell, G. C. (2007). New hepatitis C guidelines for the Asia–Pacific region: APASL consensus statements on the diagnosis, management and treatment of hepatitis C virus infection, Wiley Online Library. 22: 607-610.
32. Din, G., et al. (2014). "Prevalence of hepatitis C virus infection among thalassemia patients: a perspective from a multi-ethnic population of Pakistan." Asian Pacific journal of tropical medicine 7: S127-S133.
33. Dominguez, J., et al. (1999). "Evaluation of a rapid immunochromatographic assay for the detection of Legionella antigen in urine samples." European Journal of Clinical Microbiology and Infectious Diseases 18: 896-898.
34. Din, G., et al. (2014). "Prevalence of hepatitis C virus infection among thalassemia patients: a perspective from a multi-ethnic population of Pakistan." Asian Pacific journal of tropical medicine 7: S127-S133.
35. Dominguez, J., et al. (1999). "Evaluation of a rapid immunochromatographic assay for the detection of Legionella antigen in urine samples." European Journal of Clinical Microbiology and Infectious Diseases 18: 896-898.
36. Dupinay, T., et al. (2013). "Discovery of naturally occurring transmissible chronic hepatitis B virus infection among Macaca fascicularis from Mauritius Island." Hepatology 58(5): 1610-1620.
37. Farrell, G. C. (2007). New hepatitis C guidelines for the Asia–Pacific region: APASL consensus statements on the diagnosis, management and treatment of hepatitis C virus infection, Wiley Online Library. 22: 607-610.
38. Forget, B. G. and H. F. Bunn (2013). "Classification of the disorders of hemoglobin." Cold Spring Harbor perspectives in medicine 3(2): a011684.
39. Galanello, R. and R. Origa (2010). "Beta-thalassemia." Orphanet journal of rare diseases 5: 1-15.
40. Gilbert, M., et al. (2001). "Pathogenesis and immune." Neurology 56(758ą765): 13.
41. Din, G., et al. (2014). "Prevalence of hepatitis C virus infection among thalassemia patients: a perspective from a multi-ethnic population of Pakistan." Asian Pacific journal of tropical medicine 7: S127-S133.
42. Dominguez, J., et al. (1999). "Evaluation of a rapid immunochromatographic assay for the detection of Legionella antigen in urine samples." European Journal of Clinical Microbiology and Infectious Diseases 18: 896-898.
43. Din, G., et al. (2014). "Prevalence of hepatitis C virus infection among thalassemia patients: a perspective from a multi-ethnic population of Pakistan." Asian Pacific journal of tropical medicine 7: S127-S133.
44. Dominguez, J., et al. (1999). "Evaluation of a rapid immunochromatographic assay for the detection of Legionella antigen in urine samples." European Journal of Clinical Microbiology and Infectious Diseases 18: 896-898.
45. Dupinay, T., et al. (2013). "Discovery of naturally occurring transmissible chronic hepatitis B virus infection among Macaca fascicularis from Mauritius Island." Hepatology 58(5): 1610-1620.
46. Farrell, G. C. (2007). New hepatitis C guidelines for the Asia–Pacific region: APASL consensus statements on the diagnosis, management and treatment of hepatitis C virus infection, Wiley Online Library. 22: 607-610.
47. Forget, B. G. and H. F. Bunn (2013). "Classification of the disorders of hemoglobin." Cold Spring Harbor perspectives in medicine 3(2): a011684.
48. Galanello, R. and R. Origa (2010). "Beta-thalassemia." Orphanet journal of rare diseases 5: 1-15.
49. Gilbert, M., et al. (2001). "Pathogenesis and immune." Neurology 56(758ą765): 13.
50. Grebely, J., et al. (2017). "Elimination of HCV as a public health concern among people who inject drugs by 2030–What will it take to get there?" Journal of the International AIDS Society 20(1): 22146.
51. Gupta, B., et al. (2018). "Yoga research a scientometric assessment of global publications output during 2007-16." Pharmacognosy Journal 10(3).
52. Hadden, J. A., et al. (2018). "All-atom molecular dynamics of the HBV capsid reveals insights into biological function and cryo-EM resolution limits." Elife 7: e32478.
53. Hanif, M., et al. (2013). "Study of genotypes and subgenotypes of Hepatitis B virus prevalent in big cities of Pakistan." Afr J Microbiol Res 7(3): 152-157.
54. Hayder, I., et al. (2012). "Comparison of Different ICT Kits for HBsAg and Anti HCV Using Gold Standard ELISA." Pakistan Journal of Medical Research 51(3).
55. Hudna, A. S., et al. (2022). "Hepatitis B and C among Multi-Transfused Pediatric Thalassemic Patients in Sana'a City, Yemen: A Single-Center Retrospective Study." Yemeni Journal for Medical Sciences 16(1): 7-13.
56. Ishida, J. H., et al. (2008). "Influence of cannabis use on severity of hepatitis C disease." Clinical gastroenterology and hepatology 6(1): 69-75.
57. Jafroodi, M., et al. (2015). "Trend in prevalence of hepatitis C virus infection among β-thalassemia major patients: 10 years of experience in Iran." International journal of preventive medicine 6.
58. Jallab, H. R. and Z. M. Eesa (2020). "Prevalence of Hepatitis B and Hepatitis C Viruses in?– thalassemias major patient in AD-Diwanya privince, iraq." Indian Journal of Forensic Medicine & Toxicology 14(2): 743-747.
59. Janjua, N. and M. Nizamy (2004). "Knowledge and practices of barbers about hepatitis B and C transmission in Rawalpindi and Islamabad." Journal of Pakistan medical association 54(3): 116.
60. Kalim, M., et al. (2017). "Detection of HBV and HCV by ICT and ELISA Method in Different Areas of District Malakand." PSM Microbiology 2(1): 5-8.
61. Kandi, V., et al. (2021). "Hepatitis C viral infection among beta-thalassemia patients: a study from the centre for excellence in thalassemia and other blood disorders." Cureus 13(7).
62. Kato, N. (2000). "Genome of human hepatitis C virus (HCV): gene organization, sequence diversity, and variation." Microbial & comparative genomics 5(3): 129-151.
63. Khalil, S., et al. (2016). "Status of hepatitis B and C in beta thalassemia major patients." Journal of Islamabad Medical & Dental College (JIMDC) 5(2): 71-73.
64. Kidson-Gerber, G. L., et al. (2008). "Management and clinical outcomes of transfusion-dependent thalassaemia major in an Australian tertiary referral clinic." Medical journal of Australia 188(2): 72-75.
65. Kusumoto, S., et al. (2020). "Ultra-high sensitivity HBsAg assay can diagnose HBV reactivation following rituximab-based therapy in patients with lymphoma." Journal of hepatology 73(2): 285- 293.
66. Lai, M. W., et al. (2012). "Increased seroprevalence of HBV DNA with mutations in the s gene among individuals greater than 18 years old after complete vaccination." Gastroenterology 143(2): 400-407.
67. Lee, S. R., et al. (2011). "Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid." Journal of virological methods 172(1-2): 27-31.
68. Li, Y.-P., et al. (2014). "Differential Sensitivity of 5′ UTR-NS5A recombinants of hepatitis C virus genotypes 1− 6 to protease and NS5A inhibitors." Gastroenterology 146(3): 812-821. e814.
69. Liang, T. J. (2009). "Hepatitis B: the virus and disease." Hepatology 49(S5): S13-S21.
70. Lindenbach, B. D. and C. M. Rice (2003). "Molecular biology of flaviviruses." Advances in virus research 59: 23-62.
71. Luby, S., et al. (1997). "The relationship between therapeutic injections and high prevalence of hepatitis C infection in Hafizabad, Pakistan." Epidemiology & Infection 119(3): 349-356.
72. MacLachlan, J. H., et al. (2015). "Estimating the global prevalence of hepatitis B." The Lancet 386(10003): 1515-1517.
73. Mahmood, M., et al. (2022). "Identification of HBV and HCV transmission in multi-transfused Thalassemia patients of Azad Jammu and Kashmir, Pakistan." medRxiv: 2022.2001. 2025.22269811.
74. Lai, M. W., et al. (2012). "Increased seroprevalence of HBV DNA with mutations in the s gene among individuals greater than 18 years old after complete vaccination." Gastroenterology 143(2): 400-407.
75. Lee, S. R., et al. (2011). "Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid." Journal of virological methods 172(1-2): 27-31.
76. Lai, M. W., et al. (2012). "Increased seroprevalence of HBV DNA with mutations in the s gene among individuals greater than 18 years old after complete vaccination." Gastroenterology 143(2): 400-407.
77. Lai, M. W., et al. (2012). "Increased seroprevalence of HBV DNA with mutations in the s gene among individuals greater than 18 years old after complete vaccination." Gastroenterology 143(2): 400-407.
78. Lee, S. R., et al. (2011). "Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid." Journal of virological methods 172(1-2): 27-31.
79. Li, Y.-P., et al. (2014). "Differential Sensitivity of 5′ UTR-NS5A recombinants of hepatitis C virus genotypes 1− 6 to protease and NS5A inhibitors." Gastroenterology 146(3): 812-821. e814.
80. Liang, T. J. (2009). "Hepatitis B: the virus and disease." Hepatology 49(S5): S13-S21.
81. Lindenbach, B. D. and C. M. Rice (2003). "Molecular biology of flaviviruses." Advances in virus research 59: 23-62.
82. Luby, S., et al. (1997). "The relationship between therapeutic injections and high prevalence of hepatitis C infection in Hafizabad, Pakistan." Epidemiology & Infection 119(3): 349-356.
83. MacLachlan, J. H., et al. (2015). "Estimating the global prevalence of hepatitis B." The Lancet 386(10003): 1515-1517.
84. Mahmood, M., et al. (2022). "Identification of HBV and HCV transmission in multi-transfused Thalassemia patients of Azad Jammu and Kashmir, Pakistan." medRxiv: 2022.2001. 2025.22269811.
85. Mahmood, M. A., et al. (2004). "Prevalence of hepatitis B, C and HIV infection in blood donors of Multan region." Annals of King Edward Medical University 10(4).
86. Mansour-Ghanaei, F., et al. (2021). "Epidemiologic profile of viral hepatitis B and C in North of Iran: results from PERSIAN Guilan Cohort Study (PGCS)." BMC Research Notes 14: 1-7.
87. Marengo-Rowe, A. J. (2007). The thalassemias and related disorders. Baylor university medical center proceedings, Taylor & Francis.
88. Mettananda, D. S. G. (2015). Ameliorating β-thalassaemia by manipulating expression of the α- globin gene, University of Oxford.
89. Mirzaei, G., et al. (2021). "Prevalence of HBV and HCV infection in beta-thalassemia major patients of Tabriz city, Iran." New Microbes and New Infections 43: 100912.
90. Mohammadi, S. and M. Khodabandehloo (2017). "Prevalence of hepatitis C virus antibodies among beta-thalassemia major patients in Kurdistan Province, Iran." ARCHIVES OF CLINICAL INFECTIOUS DISEASES 12(3).
91. Mukherjee, K., et al. (2017). "Prevalence of hepatitis B and hepatitis C virus infection in repeatedly transfused thalassemics in a tertiary care hospital in eastern India." Int J Res Med Sci 5(10): 4558- 4562.
92. Mumtaz, K., et al. (2005). "Epidemiology and clinical pattern of hepatitis delta virus infection in Pakistan." Journal of gastroenterology and hepatology 20(10): 1503-1507.
93. Musa, B., et al. (2015). "Prevalence of hepatitis B virus infection in Nigeria, 2000-2013: a systematic review and meta-analysis." Nigerian journal of clinical practice 18(2): 163-172.
94. NADIR, R., et al. "Frequency of Hepatitis B and C in Beta Thalassemia Major with Multiple Blood Transfusions."
95. Nagral, A., et al. (2017). "Generic direct acting antivirals in treatment of chronic hepatitis C infection in patients of thalassemia major." Journal of clinical and experimental hepatology 7(3): 172-178.
96. Nguyen, D. H., et al. (2008). "Hepatitis B virus–cell interactions and pathogenesis." Journal of cellular physiology 216(2): 289-294.
97. Nienhuis, A. W. and D. G. Nathan (2012). "Pathophysiology and clinical manifestations of the β- thalassemias." Cold Spring Harbor perspectives in medicine 2(12): a011726.
98. Noguchi, C., et al. (2004). "Reducing oxidative damage and cell dehydration in thalassemia." Haematologica 89: 1281-1283.
99. Mohammadi, S. and M. Khodabandehloo (2017). "Prevalence of hepatitis C virus antibodies among beta-thalassemia major patients in Kurdistan Province, Iran." ARCHIVES OF CLINICAL INFECTIOUS DISEASES 12(3).
100. Mukherjee, K., et al. (2017). "Prevalence of hepatitis B and hepatitis C virus infection in repeatedly transfused thalassemics in a tertiary care hospital in eastern India." Int J Res Med Sci 5(10): 4558- 4562.
101. Mumtaz, K., et al. (2005). "Epidemiology and clinical pattern of hepatitis delta virus infection in Pakistan." Journal of gastroenterology and hepatology 20(10): 1503-1507.
102. Musa, B., et al. (2015). "Prevalence of hepatitis B virus infection in Nigeria, 2000-2013: a systematic review and meta-analysis." Nigerian journal of clinical practice 18(2): 163-172.
103. NADIR, R., et al. "Frequency of Hepatitis B and C in Beta Thalassemia Major with Multiple Blood Transfusions."
104. Nagral, A., et al. (2017). "Generic direct acting antivirals in treatment of chronic hepatitis C infection in patients of thalassemia major." Journal of clinical and experimental hepatology 7(3): 172-178.
105. Nguyen, D. H., et al. (2008). "Hepatitis B virus–cell interactions and pathogenesis." Journal of cellular physiology 216(2): 289-294.
106. Nienhuis, A. W. and D. G. Nathan (2012). "Pathophysiology and clinical manifestations of the β- thalassemias." Cold Spring Harbor perspectives in medicine 2(12): a011726.
107. Noguchi, C., et al. (2004). "Reducing oxidative damage and cell dehydration in thalassemia." Haematologica 89: 1281-1283.
108. Origa, R. (2023). "Hepatitis C and Thalassemia: A Story with (Almost) a Happy Ending." Pathogens 12(5): 683.
109. Page, K., et al. (2013). "Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention." Clinical infectious diseases 57(suppl_2): S32-S38.
110. Parkash, A., et al. (2022). "Effectiveness And Safety Of Direct Acting Antiviral Agents In Thalassaemic Patients With Chronic Hepatitis C." Journal of Ayub Medical College, Abbottabad: JAMC 34(3): 447-451.
111. Patel, P., et al. (2012). "Rapid HIV screening: missed opportunities for HIV diagnosis and prevention." Journal of Clinical Virology 54(1): 42-47.
112. Peeling, R. W., et al. (2006). "Rapid tests for sexually transmitted infections (STIs): the way forward." Sexually transmitted infections 82(suppl 5): v1-v6.
113. Pol, S., et al. (2012). "Hepatitis C: epidemiology, diagnosis, natural history and therapy." Hepatitis C in renal disease, hemodialysis and transplantation 176: 1-9.
114. Puno, S. N., et al. (2021). Prevalence of Hepatitis B and Hepatitis C Among Patients of Thalassemia Major at a Teaching Hospital in Larkana. Med. Forum.
115. Qurat-ul-Ain, L. A., et al. (2011). "Prevalence of β-thalassemic patients associated with consanguinity and anti-HCV-antibody positivity–a cross sectional study." Pak J Zool 43(1): 29-36.
116. Riaz, M., et al. (2022). "Prevalence of transfusion-transmitted infections in multiple blood transfusion-dependent thalassemic patients in Asia: A systemic review." International Journal of Immunopathology and Pharmacology 36: 03946320221096909.
117. Schweitzer, A., et al. (2015). "Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013." The Lancet 386(10003): 1546-1555.
118. Seeger, C. and W. S. Mason (2000). "Hepatitis B virus biology." Microbiology and molecular biology reviews 64(1): 51-68.
119. Shahzadi, N., et al. (2023). "Efficacy of Sofosbuvir and Ribavirin in Children Presenting with Hepatitis C at Tertiary Care Hospital, Faisalabad." Journal of Bahria University Medical and Dental College 13(02): 82-86.
120. Silva, A. P. d. (2015). Desenvolvimento de métodos de diagnóstico, silenciamento gênico e caracterização molecular do vírus herpes simples tipo 1 e herpesvírus humano tipo 6 em pacientes imunocomprometidos do Rio de Janeiro.
121. Sinha, M. K., et al. (2019). "Menace of Hepatitis C virus among multitransfused thalassemia patients in Balasore district of Odisha state in India." Journal of Family Medicine and Primary Care 8(9): 2850.
122. Sluis-Cremer, N. and G. Tachedjian (2008). "Mechanisms of inhibition of HIV replication by non- nucleoside reverse transcriptase inhibitors." Virus research 134(1-2): 147-156.
123. Smith-Palmer, J., et al. (2015). "Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits." BMC infectious diseases 15(1): 1-19.
124. Stanaway, J. D., et al. (2016). "The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013." The Lancet 388(10049): 1081-1088.
125. Strader, D. B., et al. (2004). "Diagnosis, management, and treatment of hepatitis C." Hepatology 39(4): 1147-1171.
126. Strehlow, A. J., et al. (2012). "Hepatitis C among clients of health care for the homeless primary care clinics." Journal of health care for the poor and underserved 23(2): 811-833.
127. Syed, F. N., et al. (2023). "Hepatitis C Virus Infection in Patients with Beta Thalassemia after Multiple Transfusions at a Tertiary Care Hospital." Pakistan Journal of Medical & Health Sciences 17(01): 363-363.
128. Tang, W., et al. (2017). "Diagnostic accuracy of tests to detect Hepatitis C antibody: a meta-analysis and review of the literature." BMC infectious diseases 17: 39-57.
129. Terrault, N. A., et al. (2018). "Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance." Hepatology 67(4): 1560-1599.
130. Thein, S. L. (2018). "Molecular basis of β thalassemia and potential therapeutic targets." Blood Cells, Molecules, and Diseases 70: 54-65.
131. Tiollais, P., et al. (1985). "The hepatitis B virus." Nature 317(6037): 489-495.
132. Tong, S. and P. Revill (2016). "Overview of hepatitis B viral replication and genetic variability." Journal of hepatology 64(1): S4-S16.
133. Torti, L., et al. (2020). "Impact of SARS CoV-2 in hemoglobinopathies with immune disfunction and epidemiology. A protective mechanism from beta chain hemoglobin defects?" Mediterranean journal of hematology and infectious diseases 12(1).
134. Valentine, W. N. and J. V. Neel (1944). "Hematologic and Genetic Study of the Transmission Of Thalassemia:(Cooley's Anemia; Mediterranean Anemia)." Archives of internal medicine 74(3): 185-196.
135. Vichinsky, E. P. (2005). "Changing patterns of thalassemia worldwide." Annals of the New York Academy of Sciences 1054(1): 18-24.
136. Vichinsky, E. P. (2009). "Alpha thalassemia major—new mutations, intrauterine management, and outcomes." ASH Education Program Book 2009(1): 35-41.
137. Vichinsky, E. P. (2013). "Clinical manifestations of α-thalassemia." Cold Spring Harbor perspectives in medicine 3(5): a011742.
138. Wahed, A., et al. (2019). "Hematology and coagulation: a comprehensive review for board preparation, certification and clinical practice."
139. Waheed, U., et al. (2019). "Evaluation of screening effectiveness of hepatitis B surface antigen and anti-HCV rapid test kits in Pakistan." Journal of Laboratory Physicians 11(04): 369-372.
140. Waheed, Y., et al. (2009). "Hepatitis C virus in Pakistan: a systematic review of prevalence, genotypes and risk factors." World journal of gastroenterology: WJG 15(45): 5647.
141. Weatherall, D. (2000). "Introduction to the Problem of Hemoglobin E-β Thalassemia." Journal of Pediatric Hematology/Oncology 22(6): 551.
142. Weatherall, D. and J. Clegg (2001). Historical perspectives: in The Thalassemia syndromes 4th edition, Blackwell Scientific, Oxford UK.
143. Torti, L., et al. (2020). "Impact of SARS CoV-2 in hemoglobinopathies with immune disfunction and epidemiology. A protective mechanism from beta chain hemoglobin defects?" Mediterranean journal of hematology and infectious diseases 12(1).
144. Valentine, W. N. and J. V. Neel (1944). "Hematologic and Genetic Study of the Transmission Of Thalassemia:(Cooley's Anemia; Mediterranean Anemia)." Archives of internal medicine 74(3): 185-196.
145. Vichinsky, E. P. (2005). "Changing patterns of thalassemia worldwide." Annals of the New York Academy of Sciences 1054(1): 18-24.
146. Vichinsky, E. P. (2009). "Alpha thalassemia major—new mutations, intrauterine management, and outcomes." ASH Education Program Book 2009(1): 35-41.
147. Vichinsky, E. P. (2013). "Clinical manifestations of α-thalassemia." Cold Spring Harbor perspectives in medicine 3(5): a011742.
148. Wahed, A., et al. (2019). "Hematology and coagulation: a comprehensive review for board preparation, certification and clinical practice."
149. Waheed, U., et al. (2019). "Evaluation of screening effectiveness of hepatitis B surface antigen and anti-HCV rapid test kits in Pakistan." Journal of Laboratory Physicians 11(04): 369-372.
150. Waheed, Y., et al. (2009). "Hepatitis C virus in Pakistan: a systematic review of prevalence, genotypes and risk factors." World journal of gastroenterology: WJG 15(45): 5647.
151. Weatherall, D. (2000). "Introduction to the Problem of Hemoglobin E-β Thalassemia." Journal of Pediatric Hematology/Oncology 22(6): 551.
152. Weatherall, D. and J. Clegg (2001). Historical perspectives: in The Thalassemia syndromes 4th edition, Blackwell Scientific, Oxford UK.
153. Whipple, G. H. and W. L. Bradford (1936). "Mediterranean disease-thalassemia (erythroblastic anemia of Cooley): associated pigment abnormalities simulating hemochromatosis." The Journal of Pediatrics 9(3): 279-311.
154. Yu, S., et al. (2020). "Burden of Acute Viral Hepatitis—China, 1990− 2019." China CDC Weekly 2(31): 579.
155. Zamani, F., et al. (2018). "The effectiveness of sofosbuvir and daclatasvir in the treatment of hepatitis C in thalassaemia major patients and their effect on haematological factors." Indian journal of medical microbiology 36(2): 224-22
Article Sidebar
Published
Aug 21, 2024
Article Details
How to Cite
Umaima Israr, Abdul Naeem, Shahbaz Saqib, Komal Abbasi, Hira Aijaz, Lama Qadri, Syed Muhammad Hameez Qadri, Hareem Mehmood, Lubna Meraj, & Usman Wajid. (2024). VIRAL INFECTION PREVALENCE IN Β-THALASSEMIA MAJOR PATIENTS RECEIVING FREQUENT BLOOD TRANSFUSIONS. Journal of Population Therapeutics and Clinical Pharmacology, 31(8), 1153-1176. https://doi.org/10.53555/jptcp.v31i8.7488
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Author Biographies
Umaima Israr
University of Health Sciences, Lahore.Abdul Naeem
Department of Critical Care Medicine, Islamabad Medical Complex, Islamabad.Shahbaz Saqib
Department of Dentistry, Liaquat University of Health Sciences, Jamshoro.Komal Abbasi
Benazir Bhutto Hospital, Rawalpindi Medical University, Rawalpindi.Hira Aijaz
Department of Dentistry, Liaquat University of Health Sciences, Jamshoro.Lama Qadri
Dow International Medical College, Karachi.Syed Muhammad Hameez Qadri
SEGi University Malaysia.Hareem Mehmood
Rawalpindi Medical University, Rawalpindi.Lubna Meraj
Department of Medicine, Benazir Bhutto Hospital, Rawalpindi Medical University, Rawalpindi.Usman Wajid
Department of Basic and Applied Chemistry, Faculty of Science and Technology, University of Central Punjab, Lahore.How to Cite
Umaima Israr, Abdul Naeem, Shahbaz Saqib, Komal Abbasi, Hira Aijaz, Lama Qadri, Syed Muhammad Hameez Qadri, Hareem Mehmood, Lubna Meraj, & Usman Wajid. (2024). VIRAL INFECTION PREVALENCE IN Β-THALASSEMIA MAJOR PATIENTS RECEIVING FREQUENT BLOOD TRANSFUSIONS. Journal of Population Therapeutics and Clinical Pharmacology, 31(8), 1153-1176. https://doi.org/10.53555/jptcp.v31i8.7488